HVTN 112/ HIV-1 rVSV

Principal Investigator(s):Greg Wilson
Objective:The purpose of this study is to evaluate the safety and tolerability of an HIV-1 nef/tat/vif, env pDNA vaccine delivered with electroporation (EP), followed by a recombinant vesicular stomatitis virus (rVSV) HIV envC vaccine boost, in healthy, HIV-uninfected adults.   Last updated March 24, 2021
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionParticipants will receive the HIV-1 nef/tat/vif, env pDNA vaccine at Day 0 and Months 1 and 3. They will receive the rVSV HIV envC vaccine boost at Months 6 and 9.
Mode of DeliveryIntramuscular
Official Code: NCT02654080
Trial Sponsors: NIAID (DAIDS-ES: 11988)
Start Date
End Date
March 25, 2016
July 1, 2019
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women